SecBot SecBot
SECBOTREPLAY Home › Report › GSK

GSK · GSK announced that its Phase III CALM-1 trial for camlipixant in…

GSK plc · 6-K filed Jul 17, 2026 at 06:50 ET

At the news

BEARISHIMPACT 5/10

6-K filed Jul 17, 2026 at 06:50 ET

GSK announced that its Phase III CALM-1 trial for camlipixant in refractory chronic cough met its primary endpoint (50mg BID at week 12), but the confirmatory CALM-2 trial failed to reach statistical significance on the same endpoint at week 24. The 25mg dose missed in both studies, and key secondary endpoints did not meet thresholds. Based on limited efficacy, GSK is discontinuing further development of camlipixant in RCC, though a Phase IIb trial in IBS-D/IBS-M continues. This is a clear pipeline setback for a mid-stage asset, though the financial impact is limited given GSK's scale ($106.9B market cap). The cross-filing context includes the 20-F annual report from March 2026, which provides baseline financial context but does not alter this filing's standalone interpretation. The cross-filing actuarial verdicts flag this as an amplifier combo (6k-activist-context + 6k-annual-context), but no activist context is present in the provided filings, so no override is applied.

  • CALM-1 met primary endpoint (camlipixant 50mg BID showed statistically significant reduction in 24-hour cough frequency vs placebo at week 12)
  • CALM-2 did not reach statistical significance on the same primary endpoint with 50mg BID at week 24
  • Camlipixant 25mg BID did not reach statistical significance in either study
  • Key secondary endpoints, including Chronic Cough Diary measure, did not meet target thresholds in either study

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access